Search clinical trials for: 31001074/paroxetine

Total 273 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

Attention Deficit Hyperactivity Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women

Healthy | Pharmacokinetics | Drug Interactions
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers

Healthy | Pharmacokinetics
Janssen Research & Development, LLC
The Scripps Research Institute

Withdrawn

Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults

Alcoholism

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
GlaxoSmithKline

Completed

Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)

Depressive Disorder

Korea, Republic of, Japan
GlaxoSmithKline

Terminated

Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)

Depressive Disorder

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation

Sexual Dysfunction | Ejaculation
Alza Corporation, DE, USA

Completed

An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation

Sexual Dysfunction | Erectile Dysfunction | Ejaculation
Johnson & Johnson Pte Ltd

Completed

The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy

Sexual Dysfunction, Physiological

Korea, Republic of, Australia, Thailand
Alza Corporation, DE, USA

Completed

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.

Ejaculation
Janssen Research & Development, LLC

Completed

An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride

Sexual Dysfunction, Physiological | Ejaculation

Germany, Spain, Portugal, Finland, Sweden, Austria
Pusan National University Hospital

Unknown

Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation

Premature Ejaculation

Korea, Republic of
Yuhan Corporation

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044

Premature Ejaculation

Korea, Republic of
GlaxoSmithKline

Completed

Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects

Depressive Disorder

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Erectile Dysfunction
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Erectile Dysfunction
Alza Corporation, DE, USA

Completed

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Ejaculation
Janssen Research & Development, LLC
Cegedim Strategic Data

Completed

PRILIGY Usage Patterns in Selected Populations

Sexual Dysfunction, Physiological
Xidian University

Unknown

Investigation of the Changes of Brain Structure and Function in Premature Ejaculation Patients and the Effects of Dapoxetine on Central Neural Activity in Premature Ejaculation Patients

Premature Ejaculation

China
University of Southern Denmark

Unknown

Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study

Depression | Pain
University of Göttingen
GlaxoSmithKline

Completed

Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder (Exparox)

Panic Disorder

Germany
GlaxoSmithKline

Completed

A Local Register Study For Major Depression Of Paroxetine Controlled Release

Depressive Disorder, Major | Major Depressive Disorder (MDD)

China
GlaxoSmithKline

Completed

Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants

Anxiety Disorders

Mexico
GlaxoSmithKline

Completed

Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects

Depressive Disorder

Japan
Dong-A Pharmaceutical Co., Ltd.
Dong-A ST Co., Ltd.

Unknown

Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine

Healthy Male Subjects

Korea, Republic of
GlaxoSmithKline

Completed

Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects

Anxiety Disorders

China
Oizumi Hospital

Unknown

Benefits of Switching Antidepressants Following Early Nonresponse

Depression

Japan
Noven Therapeutics

Completed

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women (N30-005)

Postmenopausal Symptoms

United States
Attenuon
Prostate Cancer Clinical Trials Consortium

Unknown

Study of ATN-224 in Patients With Prostate Cancer

Prostate Cancer

United States
Noven Therapeutics

Completed

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) (N30-003)

Postmenopausal Symptoms

United States
Noven Therapeutics

Completed

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Hot Flashes

United States
Sohag University

Completed

Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature Ejaculation (PE)

Premature Ejaculation

Egypt
GlaxoSmithKline

Completed

Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine

Depression, Postpartum
Altamash Institute of Dental Medicine

Completed

Effect of Occlusal Reduction on Relief of Pain and Sensitivity to Percussion in Patients With Irreversible Pulpitis

Post Operative Pain | Post-Op Complication

Pakistan
Noven Therapeutics

Completed

Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

Hot Flashes

United States
Federal University of Pelotas

Completed

Botox vs Occlusal Splint for Masseter Pain

Pain, Face

Brazil
Foundation for Atlanta Veterans Education and Research...
Emory University

Terminated

Neural Correlates of Early Intervention for Posttraumatic Stress Disorder (PTSD)

Posttraumatic Stress Disorder (PTSD)

United States
University of Pittsburgh
GlaxoSmithKline

Completed

Paroxetine in the Treatment of Chronic Primary Insomnia

Depression | Primary Insomnia

United States
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
LanZhou University; Beijing Friendship Hospital; The Third Affiliated Hospital... and other collaborators

Recruiting

A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema

Eczema

China
Cairo University

Completed

Occlusal Reduction Effect on Postendodontic Pain

Symptomatic Irreversible Pulpitis
University of Barcelona

Recruiting

Effectiveness of Two Oral Appliances for Managing Oral Self-biting Injuries in Patients With ALS

Satisfaction

Spain
Anthera Pharmaceuticals

Completed

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Treatment Of Patients With Social Anxiety Disorder

Social Phobia

United States, Canada, Germany, Sweden, Finland, Norway, South Africa
GlaxoSmithKline

Completed

Depression Study In Elderly Patients

Depressive Disorder, Major | Major Depressive Disorder (MDD)

United States
MorePharma Corporation

Completed

Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation

Premature Ejaculation

Mexico
Inje University
GlaxoSmithKline

Unknown

Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release

Panic Disorder

Korea, Republic of

3

Subscribe